Communiqués BriaCell Therapeutics Corp. Nasdaq

Actions

BCTX

CA1079303071

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 06/08/2026			Varia. 5j.	Varia. 1 janv.
3,450 ^USD	-1,43 %		-4,96 %	-51,48 %

05/08	BriaCell reçoit le feu vert de la FDA pour lancer l'étude de phase 1/2a de son immunothérapie contre le cancer de la prostate	MT
05/08	BriaCell Therapeutics Corp reçoit le feu vert de la FDA pour lancer l'étude clinique Bria-PROS+ dans le cancer de la prostate	CI

Communiqués

05/08	BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer	AQ
16/07	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT	AQ
16/07	BriaCell Therapeutics : Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer	PU
16/07	BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer	AQ
15/07	BriaCell Therapeutics : Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT(TM)	PU
15/07	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™	AQ
07/07	BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™	AQ
25/06	BriaCell Therapeutics : Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)	PU
25/06	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™	AQ
02/06	BriaCell Therapeutics Announces Closing of Offering	AQ
01/06	BriaCell Presents Positive Clinical Data at ASCO 2026	AQ
01/06	BriaCell Therapeutics Announces Pricing of Offering	AQ
26/05	BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer	AQ
22/05	BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026	AQ
18/05	BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+	AQ
15/05	BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™	AQ
14/05	BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer	AQ
13/05	BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study	AQ
12/05	BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients	AQ
11/05	BriaCell Therapeutics : Investor Presentation (2026May11 Investor Presentation website Final)	PU
11/05	BriaCell Therapeutics : Investor Presentation (2026May11 Investor Presentation website )	PU
07/05	BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study	AQ
06/05	BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer	AQ
27/04	BriaCell Announces Six Clinical Data Presentations at ASCO 2026	AQ
21/04	BriaCell Therapeutics : Fact Sheet (20260421 Fact Sheet)	PU